Theralink Technologies, Inc. (THER)
| Previous close | 0.0040 |
| Open | 0.0036 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.0036 - 0.0040 |
| 52-week range | 0.0028 - 7.0000 |
| Volume | |
| Avg. volume | 5,749,069 |
| Market cap | 22.145M |
| Beta (5Y monthly) | 25.34 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0010 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Theralink® Technologies to Host Fireside Chat with Dr. Mick Ruxin, President and Chief Executive Officer, on June 22nd at 11:00 a.m. ET
Theralink Technologies (OTC: THER) ("Theralink" or the "Company"), a precision medicine company with a novel phosphoprotein-based assay for breast cancer, today announced that it will host a virtual fireside chat with its President & CEO, Mick Ruxin, M.D., on Wednesday, June 22nd at 11:00am ET, 2022.
- PR Newswire
Theralink® Technologies Expands Adoption of its Precision Medicine Technology in the Biopharmaceutical Industry
Theralink Technologies (OTC: THER) ("Theralink" or the "Company"), a precision medicine company with a novel phosphoprotein-based assay for breast cancer, today announced that it has significantly expanded the adoption of its Laser Capture Microdissection (LCM) and Reverse Phase Protein Array (RPPA) precision medicine technology to biopharmaceutical companies, including multinational healthcare corporations. The Company has supported 41 preclinical and clinical studies for 18 biopharma companies
- PR Newswire
Avera Health and Theralink® Technologies Announce Strategic Collaboration to Accelerate Adoption of Precision Oncology and Personalized Cancer Care
Avera Health (Avera), an integrated regional health care system that serves 300 locations across the Upper Midwest, and Theralink Technologies (OTC: THER) ("Theralink" or the "Company"), a precision medicine company with a novel phosphoprotein-based assay for breast cancer today announced a strategic collaboration to advance comprehensive molecular profiling, enabling Avera Health's providers and patients to benefit from data-driven insights that inform targeted cancer treatments.
